Steve Seedhouse
Stock Analyst at Cantor Fitzgerald
(2.45)
# 2,400
Out of 5,156 analysts
17
Total ratings
62.5%
Success rate
-1.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steve Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HROW Harrow | Maintains: Overweight | $94 → $91 | $35.15 | +158.89% | 2 | Mar 4, 2026 | |
| BLTE Belite Bio | Maintains: Overweight | $200 → $266 | $179.12 | +48.50% | 2 | Mar 3, 2026 | |
| SRZN Surrozen | Initiates: Overweight | $40 | $27.09 | +47.66% | 1 | Feb 19, 2026 | |
| WVE Wave Life Sciences | Maintains: Overweight | $34 → $41 | $13.29 | +208.50% | 2 | Feb 5, 2026 | |
| KRRO Korro Bio | Upgrades: Overweight | $21 | $12.30 | +70.73% | 2 | Jan 28, 2026 | |
| APLS Apellis Pharmaceuticals | Maintains: Overweight | $39 → $35 | $19.99 | +75.09% | 2 | Jan 13, 2026 | |
| XNCR Xencor | Maintains: Overweight | $40 → $42 | $11.87 | +253.83% | 2 | Nov 6, 2025 | |
| INVA Innoviva | Maintains: Overweight | $29 → $31 | $22.32 | +38.89% | 2 | Nov 6, 2025 | |
| CAMP Camp4 Therapeutics | Initiates: Overweight | $7 | $6.28 | +11.55% | 1 | Oct 2, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Overweight | $52 | $3.98 | +1,206.53% | 1 | Jul 11, 2025 |
Harrow
Mar 4, 2026
Maintains: Overweight
Price Target: $94 → $91
Current: $35.15
Upside: +158.89%
Belite Bio
Mar 3, 2026
Maintains: Overweight
Price Target: $200 → $266
Current: $179.12
Upside: +48.50%
Surrozen
Feb 19, 2026
Initiates: Overweight
Price Target: $40
Current: $27.09
Upside: +47.66%
Wave Life Sciences
Feb 5, 2026
Maintains: Overweight
Price Target: $34 → $41
Current: $13.29
Upside: +208.50%
Korro Bio
Jan 28, 2026
Upgrades: Overweight
Price Target: $21
Current: $12.30
Upside: +70.73%
Apellis Pharmaceuticals
Jan 13, 2026
Maintains: Overweight
Price Target: $39 → $35
Current: $19.99
Upside: +75.09%
Xencor
Nov 6, 2025
Maintains: Overweight
Price Target: $40 → $42
Current: $11.87
Upside: +253.83%
Innoviva
Nov 6, 2025
Maintains: Overweight
Price Target: $29 → $31
Current: $22.32
Upside: +38.89%
Camp4 Therapeutics
Oct 2, 2025
Initiates: Overweight
Price Target: $7
Current: $6.28
Upside: +11.55%
Tvardi Therapeutics
Jul 11, 2025
Initiates: Overweight
Price Target: $52
Current: $3.98
Upside: +1,206.53%